Table 1.
Vascular endothelial growth facto levels, central macular thickness, and best-corrected visual acuity before and after intravitreal injection of bevacizumab in neovascular age macular degeneration
| Baseline | 7d | 30d | 3 m | |
|---|---|---|---|---|
| VEGF (pg/mL) | 179.7 ± 88.369 | 44.2 ± 25.258 | 56.6 ± 17.788 | 84.4 ± 23.378 |
| P < 0.0001 | P < 0.0001 | P < 0.0001 | ||
| BCVA (decimal) | 0.044 ± 0.062 | 0.079 ± 0.079 | 0.102 ± 0.085 | 0.084 ± 0.075 |
| P 0.0020 | P < 0.0001 | P 0.0005 | ||
| SD-OCT | ||||
| CRT (μm) | 407.0 ± 190.374 | 307.9 ± 94.128 | 294.8 ± 104.173 | 334.3 ± 104.904 |
| P 0.0018 | P 0.0005 | P 0.0198 | ||
| MV (mm3) | 11.992 ± 3.740 | 10.700 ± 2.325 | 10.338 ± 2.286 | 10.867 ± 2.290 |
| P 0.0346 | P 0.0074 | P 0.0647 | ||
| MA (μm) | 332.5 ± 104.318 | 297.7 ± 64.979 | 287.4 ± 63.545 | 299.6 ± 65.462 |
| P 0.0420 | P 0.0091 | P 0.0543 | ||
VEGF vascular endothelial growth factor, BCVA best-corrected visual acuity, SD-OCT spectral-domain optical coherence tomography, CRT central retinal thickness, MV macular volume, MA macular area, P P value (comparisons with baseline)
* Linear mixed models were used to compare time points